S. Wolters

Faculty of Medical Sciences

Telephone:

E-mail:

s.wolters umcg.nl

ORCID Research Portal

Publications

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

Wolters, S., Carpay, J. A., Pronk, M. H., Zuurbier, K. W. M., Driessen, M. T., Lyras, L. & Postma, M. J., 24-Jun-2024, In: BMC NEUROLOGY. 24, 1, 12 p., 214.

Research output: Contribution to journal › Article › Academic › peer-review

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies: can alignment be improved?

Wolters, S., de Jong, L. A., Jansen, C., Jansman, F. G. A. & Postma, M. J., 2024, In: Expert Review of Pharmacoeconomics and Outcomes Research. 24, 2, p. 251-265 15 p.

Research output: Contribution to journal › Article › Academic › peer-review

Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands

Velikanova, R., Wolters, S., Hofstra, H. S., Postma, M. J. & Boersma, C., Sept-2024, In: Journal of market access & health policy. 12, 3, p. 181-198 18 p.

Research output: Contribution to journal › Article › Academic › peer-review

Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade

Westerink, L., Wolters, S., Zhou, G., Postma, A., Boersma, C., van Boven, J. F. M. & Postma, M. J., 30-Aug-2024, (E-pub ahead of print) In: European Journal of Health Economics.

Research output: Contribution to journal › Article › Academic › peer-review

Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?

Wolters, S., Jansman, F. G. A. & Postma, M. J., Dec-2022, In: Value in Health. 25, 12, p. 1958-1966 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

All (5) publications

View full research profile